



May 12, 2022

To: All Concerned Parties

Company Name: Solasia Pharma K.K.
Representative: Yoshihiro Arai, President & CEO
(Code number: 4597, TSE Growth Section)
Contact: Toshio Miyashita, CFO, Director
Tel: 81-3-5843-8046
URL: <https://solasia.co.jp/en/>

Solasia announces SP-03 episil® Business

Tokyo, Japan, May 12, 2022 – Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai; “Solasia”), a specialty pharmaceutical company based in the Asian region, hereby announces that, as of today, there is a difference of opinion with Camurus AB (“Camurus”) regarding the continuity of the LICENSE AND DISTRIBUTION AGREEMENT for our development product SP-03 episil® business. At least for the time being, product supply of SP-03 episil® will be maintained. Solasia is currently engaging in discussions with Camurus to resolve this issue.

###